KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Enterprise Value (2016 - 2025)

Gilead Sciences (GILD) has disclosed Enterprise Value for 17 consecutive years, with -$7.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value rose 24.09% year-over-year to -$7.6 billion, compared with a TTM value of -$7.6 billion through Dec 2025, up 24.09%, and an annual FY2025 reading of -$7.6 billion, up 24.09% over the prior year.
  • Enterprise Value was -$7.6 billion for Q4 2025 at Gilead Sciences, down from -$7.4 billion in the prior quarter.
  • Across five years, Enterprise Value topped out at -$2.9 billion in Q2 2024 and bottomed at -$10.1 billion in Q4 2024.
  • Average Enterprise Value over 5 years is -$5.9 billion, with a median of -$5.6 billion recorded in 2022.
  • The sharpest move saw Enterprise Value skyrocketed 80.5% in 2021, then plummeted 85.47% in 2025.
  • Year by year, Enterprise Value stood at -$6.5 billion in 2021, then increased by 1.67% to -$6.4 billion in 2022, then decreased by 14.53% to -$7.3 billion in 2023, then crashed by 37.11% to -$10.1 billion in 2024, then rose by 24.09% to -$7.6 billion in 2025.
  • Business Quant data shows Enterprise Value for GILD at -$7.6 billion in Q4 2025, -$7.4 billion in Q3 2025, and -$5.3 billion in Q2 2025.